Tumour PSA Array

Tumour markers are proteins found in the blood, tissue or urine that may be directly produced by a tumour or by other tissues in response to the presence of a tumour.

Prostate cancer is the second most common cause of cancer in men. If it is detected early enough, it has a 90% cure rate. Carcinoembryonic Antigen (CEA), a non-specific cancer antigen produced in response to malignant cells, is measured in addition to total and free Prostate Specific Antigen (PSA). Therefore, testing for CEA simultaneously with PSA provides a more accurate diagnosis of prostate cancer. Randox Tumour PSA Array enables the simultaneous determination of these antigens in a single sample.


Tumour PSA Array

  • Free Prostate Specific Antigen (fPSA)
  • Total Prostate Specific Antigen (tPSA)
  • Carcinoembryonic Antigen (CEA)

Benefits of the Randox Tumour PSA Array

  • Multiplex testing from a single sample
  • Suitable for human serum samples
  • Small sample volume
  • Excellent analytical performance
  • Fast throughput
  • Applicable to both fully automated and semi-automated Evidence analysers
Clinical Laboratory Survey